High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)

NCT04126460 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

41

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Cancer

Interventions

DRUG: Toripalimab

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University